A 59-year-old man with HFrEF (EF 28%), T2D, and CKD stage 3b is euvolemic on ACEi, beta-blocker, MRA, and SGLT2 inhibitor. He remains symptomatic (NYH...

Question

A 59-year-old man with HFrEF (EF 28%), T2D, and CKD stage 3b is euvolemic on ACEi, beta-blocker, MRA, and SGLT2 inhibitor. He remains symptomatic (NYHA II-III). Which additional therapy is evidence-based for selected patients with persistent symptoms and elevated NT-proBNP?

Accepted Answer

Vericiguat

Answer

Hydralazine-isosorbide dinitrate in all patients regardless of race/symptoms

Answer

Long-term IV inotropes

Answer

Routine digoxin for all

Answer

Trimetazidine

us-abim MCQ (SBA): Heart Failure (HFrEF)

A 59-year-old man with HFrEF (EF 28%), T2D, and CKD stage 3b is euvolemic on ACEi, beta-blocker, MRA, and SGLT2 inhibitor. He remains symptomatic (NYHA II-III). Which additional therapy is evidence-based for selected patients with persistent symptoms and elevated NT-proBNP?